Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells
Open Access
- 12 September 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (9) , e0183275
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype. The high rate of metastasis associated to the fact that these cells frequently display multidrug resistance, make the treatment of metastatic disease difficult. Development of antitumor metal-based drugs was started with the discovery of cisplatin, however, the severe side effects represent a limitation for its clinical use. Ruthenium (Ru) complexes with different ligands have been successfully studied as prospective antitumor drugs. In this work, we demonstrated the activity of a series of biphosphine bipyridine Ru complexes (1) [Ru(SO4)(dppb)(bipy)], (2) [Ru(CO3)(dppb)(bipy)], (3) [Ru(C2O4)(dppb)(bipy)] and (4) [Ru(CH3CO2)(dppb)(bipy)]PF6 [where dppb = 1,4-bis(diphenylphosphino)butane and bipy = 2,2’-bipyridine], on proliferation of TNBC (MDA-MB-231), estrogen-dependent breast tumor cells (MCF-7) and a non-tumor breast cell line (MCF-10A). Complex (4) was most effective among the complexes and was selected to be further investigated on effects on tumor cell adhesion, migration, invasion and in apoptosis. Moreover, DNA and HSA binding properties of this complex were also investigated. Results show that complex (4) was more efficient inhibiting proliferation of MDA-MB-231 cells over non-tumor cells. In addition, complex (4) was able to inhibit MDA-MB231 cells adhesion, migration and invasion and to induce apoptosis and inhibit MMP-9 secretion in TNBC cells. Complex (4) should be further investigated in vivo in order to stablish its potential to improve breast cancer treatment.Keywords
Funding Information
- FAPESP (2013/00798-2, 2015/24940-8)
This publication has 42 references indexed in Scilit:
- A Simplified Method for Quantifying Cell Migration/Wound Healing in 96-Well PlatesSLAS Discovery, 2010
- The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR ExperimentsClinical Chemistry, 2009
- Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compoundJournal of Pharmaceutical and Biomedical Analysis, 2008
- DNA binding mode of ruthenium complexes and relationship to tumor cell toxicityDrug Resistance Updates, 2006
- From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)Journal of Inorganic Biochemistry, 2006
- Promoting apoptosis as a strategy for cancer drug discoveryNature Reviews Cancer, 2005
- Alternagin-C, a disintegrin-like protein from the venom of Bothrops alternatus, modulates alpha2ß1 integrin-mediated cell adhesion, migration and proliferationBrazilian Journal of Medical and Biological Research, 2005
- Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-AEuropean Journal of Cancer, 2004
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- IN-VITRO CLONOGENIC ASSAY FOR PREDICTING RESPONSE OF OVARIAN CANCER TO CHEMOTHERAPYThe Lancet, 1980